Biogen announces initiation of dosing in TRANSCEND
Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...
pharmaphorum2d
Biogen shows its IgAN hand with felzartamab data
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...
Seeking Alpha29d
Biogen targets $15.25-$16.25 EPS for 2025 amid LEQEMBI growth and cost savings
Biogen remains focused on advancing its immunology and rare disease pipeline, including three Phase 3 trials for Felzartamab in 2025. Q4 non-GAAP diluted EPS was $3.44 compared to analysts ...
The Nasdaq is Cratering But REGN, BIIB and CSGP Are Up Big Today
Markets are tanking on tariff fears, inflationary concerns and now fears of recession. “Given this is so uncertain and that ...
Nasdaq3d
Biogen Initiates Phase 3 TRANSCEND Study to Evaluate Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients
"I am pleased to see Biogen enroll the first patient in the Phase 3 TRANSCEND study of felzartamab in AMR and look forward to the trial’s continued enrollment.” TRANSCEND is a two-part ...
Seeking Alpha29d
Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript
Biogen's development organization had another ... is only the third agent with a positive global Phase III study in SLE. Additionally, Felzartamab was granted orphan drug designation in the ...